$1.08
0.93%
Nasdaq, Tue, Oct 20 2026.
ISIN
US74754R1032
Symbol
QLGN

Qualigen Therapeutics Inc Stock price

$1.08
-0.03 2.70% 1M
-0.29 21.17% 6M
-1.26 53.85% YTD
-2.85 72.52% 1Y
-41.16 97.44% 3Y
-588.92 99.82% 5Y
-337,498.92 100.00% 10Y
-619,998.92 100.00% 20Y
Nasdaq, Closing price Tue, Oct 20 2026
+0.01 0.93%
ISIN
US74754R1032
Symbol
QLGN
Industry

Is Qualigen Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,109 stocks worldwide.

Key metrics

Basic
Market capitalization
-
Enterprise Value
-
Net debt
$3.3m
Cash
$330.0k
Shares outstanding
1.6m
Valuation
P/E
negative
P/S | estimate
- | -
EV/Sales | estimate
- | -
EV/FCF | ex SBC
- | -
P/B
-
Financial Health
Equity Ratio
57.2%
Return on Equity
-
ROCE
372.4%
ROIC
-338.0%
Debt/Equity
-2.2
Share-Based Compensation & Dilution
SBC | % of Revenue
$40.0k | -
SBC as % of FCF
-
SBC Growth 1Y
-87.1%
Share Count Growth 1Y
763.2%
Shareholder Yield
-763.2%
Financials
Revenue | estimate
$0.0 | $0.0
EBITDA
-
EBIT
$-6.2m
Net Income
$-7.0m
Free Cash Flow | ex SBC
$-6.8m | $-6.8m
Growth
Revenue | estimate
- | -
EBITDA
-
EBIT
24.7%
Net Income
28.3%
Free Cash Flow
3.4%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow | ex SBC
- | -
More
EPS
$-4.2
FCF per Share
$-4.1
Short interest
18.8%
Employees
4
Rev per Employee
-

Qualigen Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Qualigen Therapeutics Inc forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Qualigen Therapeutics Inc forecast:

Buy
86%
Hold
14%

Financial data from Qualigen Therapeutics Inc

Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 6.05 6.05
39% 39%
-
- Research and Development Expense 0.17 0.17
96% 96%
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -6.18 -6.18
25% 25%
-
Net Profit -7.01 -7.01
28% 28%
-

In millions USD.

Don't miss a Thing! We will send you all news about Qualigen Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. The company's cancer therapeutics pipeline includes ALAN (AS1411-GNP), RAS-F3 and STARS™. ALAN (AS1411-GNP) is a DNA coated gold nanoparticle cancer drug candidate that has the potential to target various types of cancer with minimal side effects. RAS-F3 is a small molecule RAS oncogene protein-protein inhibitor for blocking RAS mutations that lead to tumor formation, especially in pancreatic, colorectal and lung cancers. STARS is a DNA/RNA-based treatment device for removal from circulating blood of precisely targeted tumor-produced and viral compounds. The company is headquartered in Los Angeles, CA.

Head office United States
CEO Mr. Richardson
Employees 4
Founded 2004
Website qlgntx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today